Antipsychotic Use Increased for Seniors With Alzheimer, Related Dementias
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 12, 2023 -- Antipsychotics are more often used by older adults receiving home health care (HHC) services with Alzheimer disease and related dementias (ADRD) versus those without ADRD, and their use is associated with worse functional outcomes, according to a study published online Sept. 6 in the Journal of the American Geriatrics Society.
Jinjiao Wang, Ph.D., R.N., from the University of Rochester in New York, and colleagues conducted a secondary analysis of 6,684 adults aged 65 years and older, with and without ADRD, receiving care from an HHC agency in 2019 to examine the prevalence and predictors of antipsychotic use and its impact on outcomes among those living with ADRD. The change in the composite activities of daily living (ADL) score from HHC admission to HHC discharge (functional outcome) was measured in 5,833 patients, where a positive score indicates improvement and a negative score indicates decline.
The researchers found that among patients with and without ADRD, the point prevalence of antipsychotic use was 17.2 and 6.6 percent, respectively. Predictors of antipsychotic use among patients living with ADRD included having greater ADL limitations, taking more medications, having behavioral and psychological symptoms, and living alone. Antipsychotic use was associated with having less ADL improvement at HHC discharge among patients living with ADRD.
"Antipsychotic use in persons with dementia is a serious patient safety issue, and it should be regularly reviewed for opportunities of deprescribing -- such as dose reduction until discontinuation -- whenever possible," Wang said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.